The introduction of an oral semaglutide medication, marketed as Wegovy pills, presents a new option for individuals seeking weight loss, offering a potentially simpler alternative to injectable treatments. However, the transition to the daily pill can involve a challenging adjustment period characterized by various gastrointestinal side effects, as detailed in a personal account.
Pharmacies in the UK began distributing the Wegovy pills in early July, with initial supplies focusing on lower doses suitable for beginners or those switching from injectable forms of semaglutide, such as Mounjaro. While not yet available on the NHS pending regulatory approval, private online pharmacies are offering the pills. The cost is positioned similarly to the Wegovy injection, around £100 for a one-month supply of the lowest dose, generally less than Mounjaro.
The oral tablets contain semaglutide, the same active ingredient found in the injectable Wegovy, but utilize a specialized coating to protect the drug from stomach acids and digestive enzymes, allowing it to be absorbed through the stomach lining. This development has generated significant interest, with expectations that it could lower costs and expand access to GLP-1 medications for individuals who are averse to injections.
Initial Adjustments and Side Effects
The author, who had previously lost 2 stone (approximately 28 pounds) on Mounjaro over 18 months, opted for the oral Wegovy seeking a more convenient daily regimen. Despite previous tolerance to Mounjaro, the switch to the pill necessitated a supply of supplementary medications for potential side effects including diarrhea, bloating, constipation, and heartburn. The screening process involved demonstrating a qualifying BMI or health condition and a commitment to long-term use for weight maintenance and associated health benefits.
The first week on the 4mg dose of the oral Wegovy was marked by a bitter taste, stress dreams, and intense sugar cravings. By day four, nausea set in, described as a mild 'yuk' feeling. Medical explanations suggest that semaglutide has a long half-life of about seven days, meaning its concentration in the body gradually builds up over approximately four to five weeks of daily dosing until a steady state is reached. While serious complications like pancreatitis are considered uncommon, particularly with potentially more gradual weight loss from the oral form, the author experienced increasing stomach pain by the end of the week.
Navigating the Second Month
Week two brought a slight weight increase, attributed to reduced physical activity. The daily dosing curve of the pill led to morning nausea that subsided, followed by evening food cravings and a desire for wine, which seemed to amplify hangover effects. An unexplained itchy rash also developed. This period was further complicated by gastrointestinal discomfort, fatigue, and diarrhea, leading to thoughts of discontinuing the medication. Support groups revealed similar struggles among other users experiencing persistent sickness and fatigue.
Despite the difficulties, the author decided to continue, noting the daily, steady suppression of appetite as a significant benefit, similar to the early stages of Mounjaro treatment. The daily pill offers a consistent effect, unlike the weekly injection which had a stronger impact immediately after administration.
Stabilization and Long-Term Outlook
By week three, the author's weight had stabilized, and a significant reduction in hunger and cravings was noted. Occasional nausea persisted, but was interpreted as a sign the medication was working. Constipation became a new issue, managed with fiber and prunes, and fatigue remained a concern. The author speculated on the potential impact on the gut microbiome.
In the fourth week, weight began to decrease noticeably, with the author reaching 11st 4lb (approximately 158 pounds). The side effects had largely subsided as the body adapted to the new regimen. The convenience of the pills for travel was highlighted, aiding resistance to temptations like cocktails and pastries. The author celebrated reaching a weight goal by ordering a subsequent month's supply, noting that predicted shortages had not materialized. While higher doses of oral Wegovy are available, the author found the 4mg dose sufficient and considered dropping to a lower maintenance dose in the future.
The absence of the side-effect care package in the second delivery was explained as a standard gesture for first-time users. The author expressed hope for future price reductions to increase accessibility, potentially driven by the upcoming launch of another GLP-1 pill, Foundayo. Ultimately, the cost savings on food and related expenses made the daily medication feel nearly free.